drugset / Trial / NCT05266196
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
Timeline
- Start
- 2022-01-15
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seclidemstat | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Topotecan | Small molecule | — | — |